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Abstract
HIV infection disturbs the central nervous system (CNS) through inflammation and glial activation. Evidence suggests roles
for microRNA (miRNA) in host defense and neuronal homeostasis, though little is known about miRNAs’ role in HIV CNS
infection. MiRNAs are non-coding RNAs that regulate gene translation through post-transcriptional mechanisms.
Messenger-RNA profiling alone is insufficient to elucidate the dynamic dance of molecular expression of the genome.
We sought to clarify RNA alterations in the frontal cortex (FC) of HIV-infected individuals and those concurrently infected
and diagnosed with major depressive disorder (MDD). This report is the first published study of large-scale miRNA profiling
from human HIV-infected FC. The goals of this study were to: 1. Identify changes in miRNA expression that occurred in the
frontal cortex (FC) of HIV individuals, 2. Determine whether miRNA expression profiles of the FC could differentiate HIV from
HIV/MDD, and 3. Adapt a method to meaningfully integrate gene expression data and miRNA expression data in clinical
samples. We isolated RNA from the FC (n=3) of three separate groups (uninfected controls, HIV, and HIV/MDD) and then
pooled the RNA within each group for use in large-scale miRNA profiling. RNA from HIV and HIV/MDD patients (n=4 per
group) were also used for non-pooled mRNA analysis on Affymetrix U133 Plus 2.0 arrays. We then utilized a method for
integrating the two datasets in a Target Bias Analysis. We found miRNAs of three types: A) Those with many dysregulated
mRNA targets of less stringent statistical significance, B) Fewer dysregulated target-genes of highly stringent statistical
significance, and C) unclear bias. In HIV/MDD, more miRNAs were downregulated than in HIV alone. Specific miRNA families
at targeted chromosomal loci were dysregulated. The dysregulated miRNAs clustered on Chromosomes 14, 17, 19, and X. A
small subset of dysregulated genes had many 39 untranslated region (39UTR) target-sites for dysregulated miRNAs. We
provide evidence that certain miRNAs serve as key elements in gene regulatory networks in HIV-infected FC and may be
implicated in neurobehavioral disorder. Finally, our data indicates that some genes may serve as hubs of miRNA activity.
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Introduction
RNA may be the most ancient form of biological phenomena,
with functions stretching from templating DNA [1] to enzymatic
self-regulation [2]. An intriguingly small, but functionally robust,
RNA species known as microRNA has proved to be at the center
of regulating genomic expression.
MicroRNAs
MiRNAs are short strands of 18-25 nucleotides that are both
evolutionarily conserved and emergent, potentially currently
undergoing evolution in vertebrates [3]. MiRNAs can be
transcribed from non-protein-coding genomic regions or intronic
regions of ‘‘host’’ genes, with which they are usually co-expressed
[4]. Pre-miRNAs are synthesized in the nucleus, possessing
characteristic hairpin loops [5]. After being exported to the
cytoplasm they are further processed by Dicer enzyme into mature
miRNAs usually of 21–23 nucleotides in length [6]. They function
in association with the RNA-induced silencing complex (RISC) to
hybridize to 8-mer ‘‘seed’’ sequences in the 39 untranslated regions
(39UTR) of target mRNAs [7]. Imperfect matching results in
interruption of translation by the ribosome and perfect seed-
sequence matching leads to cleavage of the target mRNA [8]. The
search for miRNA targets has been largely bioinformatics-based
(the Sanger database is an excellent archive of information on pre-,
mature- miRNAs, host genes, chromosomal location, and targets
[9]). A schematic representation of the biology of miRNA is
illustrated in Figure 1a.
MicroRNAs in Host Defense. Several recently published
reports have demonstrated a complex interplay of viral products
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miRNA and virus interaction is the co-opting of miR-122 for
replication by the hepatitis C virus, possibly explaining the
predilection of hepatitis C for the liver. A microRNA link to viral
tropism has also been suggested for HIV by Xu Wang and
colleagues with their finding that specific miRNAs in monocytes
may confer resistance to HIV infection in monocytes and loss of
these miRNAs in macrophages increases susceptibility to infection
[10]. MiRNA abundances can also change in response to various
viral infections. A miRNA profile of peripheral blood mononuclear
cells in HIV-infected individuals demonstrated that at least 62
miRNAs are altered in HIV infection [11]. A string of papers has
even suggested that HIV can have a generalized suppressive effect
uponthemiRNAbiogenesispathway,possiblythroughinhibition of
DICER [12,13], however this finding is controversial.
MicroRNAs in the Central Nervous System. A growing
body of evidence supports a role for miRNAs in neural patterning,
neuronal maintenance and neurodegeneration. Kapsimali et al
found that miRNAs have variable expression profiles in the
developing and mature brain, demonstrating differences across the
lifespan of a cell [14]. MiR-92b varies in expression during the
transition from proliferation to differentiation of neurons, while
miR-124 is constitutively expressed in mature neurons. Lau and
colleagues identified 43 miRNAs with dynamic expression during
transition from progenitor cells to mylenating mature
oligodendrocytes miRNAs [15]. Unsurprisingly, miRNAs can be
regionally specific, as evidenced by miR-222 which is restricted to
the telecephalon [14]. MiRNAs can also be cell-type specific, e.g.
the motor-neuron specific miR-218 [14].
MiRNAs have been implicated in neurodegenerative diseases
such as: Alzheimer’s, Parkinson’s, and Huntington’s chorea.
MiRNA expression profiling of CNS tissue from patients with
sporadic Alzheimer’s disease revealed 13 dysregulated miRNAs,
which included those with putative binding sites in the 39UTR of
amyloid precursor protein [16]. Kim and coworkers described a
regulatory feedback network in midbrain dopaminergic cells
whereby miR133-b and the gene Pitx3 regulate tyrosine
hydroxylase function, possibly contributing to Parkinson’s patho-
physiology [17]. In the FC of Huntington’s Disease patients, miR-
132 was found to be significantly downregulated possibly resulting
in increased levels of RE1-silencing transcription factor (REST), a
protein with potential implications in neuropathogenesis [18].
MicroRNAs in NeuroAIDS. Given that miRNAs play a role
in development and homeostasis of the CNS, and also are affected
by and affect the properties of viral infection, it is important to
clarify the interplay between miRNAs and HIV in the CNS and
how they correlate with common clinical co-morbidities such as
MDD. Interestingly, Eletto and colleagues found that HIV-Tat
may promote miR-128a activity, leading to a reduction in
SNAP25 expression in neurons [19,20]. Neurologic dysfunction
is likely influenced by overlapping mechanisms of miRNA
dysregulation in neurodegenerative disorders, psychiatric
disorders, and/or infectious diseases.
In the post-genome era, large-scale gene expression arrays have
been employed to uncover biological processes of cellular function,
tissue development, and biomedical pathologies. Message RNA
profiling has been useful in identifying gene networks that coalesce
into functional outcomes. However, gene expression arrays are
informative for only one level in the central dogma of molecular
biology: transcription from DNA to RNA. Translation of RNA to
protein, involves regulatory factors that also affect downstream
molecular outcomes. This report presents a snapshot of two levels
Figure 1. MicroRNA Profile of Frontal Cortex in HIV and HIV/MDD. (A) Summary of the biology of miRNAs. MiRNAs are synthesized in the
nucleus and transported to the cytoplasm where they undergo processing by DROSHA and Dicer to mature miRNAs, which are presented by the RISC
complex to hybridize to target sequences in the 39UTR of mRNAs, where either translation is interrupted or mRNA is degraded. (B) Heat Map of
miRNA Expression. While many miRNAs are not altered, a subset is upregulated and a smaller set downregulated in HIV. (C) MiRNA Expression of HIV
vs HIV/MDD. Those whose expressions values fall on the x=y line would be contributed by HIV and those off of the line would presumably be related
to MDD, more miRNA expression appears suppressed in the MDD context compared to HIV alone. (D) Venn Diagram of miRNAs expressed in the
various groups. Supplementary Files S1 and S2 were used to generate (A) and (B) and can be manipulated using Gene Pattern software.
doi:10.1371/journal.pone.0010337.g001
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human frontal cortex (FC) autopsy tissue.
We present the first published large-scale profiling of miRNAs
in the frontal cortex of HIV and HIV/MDD individuals. Our
three goals were to: identify changes in the miRNA profile in the
CNS associated with HIV-infection, determine whether a clinical
diagnosis of MDD in the setting of HIV-infection alters miRNA
profiles, and integrate miRNA expression with gene expression
data in order to identify correlations of miRNAs with their
putative targets in the CNS.
Results
Baseline Characteristics
RNA was isolated from 3–4 individuals of three selected groups:
control, HIV, and HIV/MDD. We attempted to match subjects
on several key variables (post-mortem interval, sex, race, age,
MDD episode within 6 months, and HIV viral load,). No subjects
met criteria for substance abuse or dependence. Table 1 displays
the demographic data for each subject. By attempting to closely-
match our subjects within and between groups it was our hope that
any observed differences in miRNA abundance were due to viral
infection and/or psychiatric diagnosis.
Quality Control and Platform Validation Results
In order to identify semi-quantitative differences in miRNA
abundance, several quality control experiments were performed to
ensure accurate amplification and rational normalization. A
‘Xeno-RNA’ assay (TaqManH Cells-to-CT
TM Control Kit,
Applied Biosystems) was performed, in which non-human,
unrelated RNA was spiked into varying dilutions of human frontal
cortex RNA stocks (pooled and non-pooled), keeping final reaction
volumes constant. A standard RT-PCR program was run and the
amplification plots were inspected to detect the presence of PCR-
inhibitors or RNAses within the isolated RNA stocks. The
amplification plots did not demonstrate any evidence of PCR-
inhibition or RNAse activity (see Supplementary Figure S1).
Furthermore, high-concentration polyacrylamide electrophoresis
of the human frontal cortex RNA failed to reveal evidence of non-
specific degradation (Supplementary Figure S1).
The selection of a stably expressed normalization microRNA
was also important in order to ensure accurate comparison
between groups. In examining the amplification plots, (Supple-
mentary Figure S2) we determined the optimal endogenous
control to be RNU44 (Accession Number NR_002750), a small
ribosomal RNA, which exhibited less sample to sample and group
to group variability. The default endogenous control for the array
platform (MammU6, Accession Number NR_004394, supplied in
quadruplicate wells on the array) exhibited lower abundance in
HIV/MDD pooled sample. When the single subject RNA samples
were subsequently analyzed, this effect was confirmed (Supple-
mentary Figure S2). The etiology of the reduced abundance of
MammU6 in HIV/MDD FC samples along with the increased
observed variability in abundance between groups remains
unclear.
To perform large-scale miRNA profiling we employed a pooled-
RNA technique. Whereby equal masses of total RNA from a
number of subjects in a group classification (Control, HIV, HIV/
MDD) were physically pooled and subjected to quantitative PCR,
a procedure that has been analyzed and modeled for microarray
experiments in Peng et al [21]. Peng et al illustrated that pooling
RNA samples was a cost-effective tool for discovery science which
yielded results representative of group by group differences, as
long as the groups are sufficiently different and defined [21]. In
order to assess the efficacy of this procedure, we compared
individual Taqman qPCR assay results from wells using single
subject RNA to wells using pooled RNA of those same individual
subjects. All analytical and mathematical procedures utilized in the
Taqman miRNA array experiments described below were kept
constant for these quality control experiments.
We verified that pooled miRNA expression results reproduced
the average of single subject values, though as modeled in Peng et
al [21], this likely represents a group difference (Supplementary
Figure S3). We chose miRNAs that were found to be upregulated,
downregulated, and not changed in the HIV and HIV/MDD
groups when compared to controls. Concordance between pooled
and single subject results were demonstrated for 9 out of 10
miRNAs selected for analysis: miRs-134, -154, -132, -122, -214, -
29a, -495, -193a, -125a. MiR-367, however, displayed discordant
results. The pooled RNA samples showed increased expression of
mir-367 in the HIV and HIV/MDD groups, while one-half of the
single subject samples from the control and HIV/MDD groups
failed to amplify. Although the groups differed on average, this was
not statistically significant (Supplementary Figure S3). For quality
control purposes, we isolated RNA from the same tissue a
second time to verify consistency of observed miRNA abundance.
We were pleased to find reproducible results (Supplementary
Figure S4).
Taqman MiRNA Array Profiles. The microfluidic miRNA
array uses a PCR-based platform, and experiments were
performed in technical triplicate. We found significant
differential expression of numerous miRNAs in HIV-infected
frontal cortex. When comparing the HIV group with Control, 59
miRNAs were up- or down-regulated by at least twofold, and in
the HIV/MDD group 78 miRNAs met these criteria. Figure 1b
shows the heatmap of the expression profiles of HIV and HIV/
MDD compared to Control (Supplementary Files S1 and S2 are
available for analysis and manipulation using Gene Pattern [22]).
Data files of these experiments are available on the Gene
Expression Omnibus (GEO) database under the accession
number GSE17491.
Each group possessed a unique subset of miRNAs, amplifying in
only that condition. The Venn diagram in Figure 1D shows that
five miRNAs were present in Control, but absent in HIV
Table 1. Characteristics of Cases in miRNA Study.
Group Study ID Pathology MDD HIVE Age PMI Sex
Control 1 Normal None n/a 50 11 M
Control 2 Normal None n/a 24 17 M
Control 3 Normal None n/a 34 9 M
HIV CC103 Min. Non-
Diganostic
abnormalities
None No 54 12 M
HIV CC141 Bacterial
leptomeningitis
None No 56 12 M
HIV CC163 Normal None No 45 12 M
HIV/MDD CA110 Encephalitis 6 Mo Yes 43 12 M
HIV/MDD CE111 Other
Non-Infect
Current No 34 10 M
HIV/MDD CE143 Normal 6 Mo No 38 7 M
Abbreviations: MDD—Major depressive disorder, 6 Mo–within six months, PMI–
post-mortem interval to autopsy, HIVE–neuropathologically confirmed HIV-
encephalitis.
doi:10.1371/journal.pone.0010337.t001
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groups and absent in Control. However, 11 miRNAs were present
in HIV and not in the MDD subjects (Figure 1D). In HIV/MDD,
those miRNAs which were expressed in both HIV and MDD,
generally showed lower expression compared to control. To
illustrate how the HIV and HIV/MDD profiles differed, the
expression values for each miRNA are displayed on a scatterplot
with HIV/MDD on the y axis and HIV on the x axis (Figure 1C).
Many miRNAs were unchanged, as indicated in the heatmap of
Figure 1B) exhibited by the clustering of points about the origin in
Figure 1C. Any miRNA whose expression fell along the x=y line
would indicate the expression levels were the same or similar in
both HIV and HIV/MDD and deviations from this line would
presumably be contributed by the presence of major depressive
disorder. Most of the points that deviated were below the line,
indicating that the cellular conditions of MDD in the frontal cortex
might involve suppression of miRNA expression.
Chromosomal Locations. We next sought to determine
whether there was a pattern with respect to chromosomal location
of the dysregulated miRNAs. MiRNAs are distributed throughout
the genome with the exception of the Y chromosome. In order to
determine whether the dysregulated miRNAs were chromo-
somally clustered near one another, we mapped the location of
the miRNAs dysregulated at least twofold (in either direction)
along the human genome using UC Santa Cruz Genome Browser
shown in Figure 2a [23]. The red points indicate miRNAs
dysregulated in HIV and in blue, HIV/MDD. The y-axis
indicates the Log2(RQ), and the x-axis indicates chromosome
number and location. A supplementary file is available for
browsing on the UCSC Genome Browser (Supplementary File
S3 [23]). As a basis for reference, all the human miRNAs are
plotted in black as annotated by the Sanger Databases [9].
Dysregulated miRNAs did seem to disproportionately cluster at
Chromosomes 14, 17, 19, and the X chromosome. Figure 2a
indicates transcriptional suppression in HIV/MDD on
Chromosomes 14 and X; and activation on Chromosome 17.
In order to formally demonstrate whether the dysregulated
miRNAs clustered closer to one another than due to chance alone,
we calculated how far apart they were on the genome compared to
choosing random miRNAs from the list of all available as in Shalgi
et al [24]. The chromosomal locations of the two-fold dysregulated
miRNAs were mapped out and the distance to the nearest-
dysregulated-neighbor of each one was calculated and we
constructed a histogram showing the distribution of distances to
nearest-neighbor-dysregulated miRNA is displayed in Figure 2b.
In HIV/MDD, the degree of clustering was more pronounced
than the degree of clustering in HIV alone. This could indicate
specific chromosomal suppression in the MDD state that is not
present in the HIV-alone state. Given that we assayed only mature
miRNAs, our observation may also indicate alterations in miRNA
processing of specific miRNA families.
MiRNAs and Gene Targets. From the same subject pool and
brain region (frontal cortex), our group compared message RNA
levels (Accession Number GSE17440) of HIV to HIV/MDD
individuals. The goalwas toidentify dysregulated mRNAexpression
signatures in order to differentiate HIV-positive subjects suffering
from MDD from those who were did not have a diagnosis of MDD.
These subjects are described in Table 2. Utilizing this mRNA data,
we performed a target bias analysis as described in Methodsin order
to determine the relationship between miRNA dysregulation and
target-gene dysregulation. Table S1 shows the ANCOVA results of
the 392 mRNA transcripts that were dysregulated in either direction
with a p-value less than 0.05. These genes are each potential targets
of miRNAs. Table S2 lists all miRNAs dysregulated $2-fold in
either direction along with any corresponding target appearing in
the ANCOVA analysis; the table is organized by miRNA and with
genes listed in ascending order of statistical significance. In order to
determine whether a dysregulated miRNA has a significant
proportion of targets dysregulated, we used the hypergeometric
probability distribution to calculate p-values to answer the question,
‘‘Given that a particular miRNA has m number of potential targets
that appear on the gene array, which has a total of N unique genes
which were detected in the FC, n of which were dysregulated at
p,0.05,whatistheprobabilitythatatleastktargetsoftheparticular
miRNA would be dysregulated?’’ SPSS was used to calculate these
probabilities for every dysregulated miRNA. In the gene array, we
calculated the exact p-values from one-way ANCOVA. Since
p,0.05 is arbitrary [25], we can calculate a target-bias probability
for any other gene-array significance window, we did this for
significancewindows ofp,0.01, p,0.005,and p,0.001 (whichhad
70, 39, and 6 genes, dysregulated respectively; shown in Table S2).
The target bias analysis is illustrated in Figure 3. The
probabilities for each window and each miRNA are visualized in
blue-shading scale indicating from lower to higher (0,p,0.5) and
white indicating 0.5,p,1. The miRNAs seemed to separate into
four general types. First, those which correlate to a larger number
of miRNAs of lower significance value, indicated by dark blue in
the p,0.05 column, for example miR-122 (Accession Number
406906), miR-589 (Accession Number 693174), and miR-423-5p
(Accession Number 494335). Second, those miRNAs which had
fewer gene-targets correlating to dysregulated mRNAs, but of
higher significance, for example miR-518b (Accession Number
574474), miR-424 (Accession Number 494336), miR-629 (Acces-
sion Number 693214), miR-22 (Accession Number 407004), and
Figure 2. Chromosomal locations of dysregulated miRNAs. (A) Map of genomic locations of miRNAs dysregulated in HIV (red) and HIV/MDD
(blue). (B) Distribution of nearest neighbor distances of dysregulated miRNAs in HIV (left) and HIV/MDD (right) and the distribution of nearest
neighbor distances if randomly chosen miRNAs were calculated. The chromosomal locations were mapped in (A) using Supplementary Files S3, S4, S5
in the UCSC Genome Browser, for comparison, locations of all human miRNAs are shown in black. For each miRNA dysregulated, the distance to the
nearest dysregulated neighbor was calculated in basepairs; and the distribution of distances was plotted in (B) along with the distribution calculated
if miRNAs were randomly chosen from all known human miRNAs and nearest miRNA were calculated.
doi:10.1371/journal.pone.0010337.g002
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blue in the p,0.001 column. Third, those miRNAs which
exhibited both patterns, namely many dysregulated gene targets
and of high significance, indicated by blue across the rows. And
finally, there were those that did not have a significant number of
dysregulated targets, indicated by white across the row.
MiR-367 (Accession Number 442912), miR-125a-3p (Accession
Number 406910), miR-502-5p (574504), and miR-136 (Accession
Number 406927) showed significant target bias across all four
windows (asterisks in Figure 3). The gene expressions (as
determined compared to HIV-alone in the microarray) which
are targets of these proteins are plotted in Figure 4.
We sought to verify in vitro, two miRNA-target pairs. We used
a lentiviral vector system to overexpress either a CDH-GFP
control vector, miR-125a, or miR-22 under control of the CMV
promoter. Vectors expressed the EGFP under the SV40 promoter.
Figure 5 shows TaqMan qPCR indicating increased levels of miR-
22 and miR-125a over time after exposure to the lentiviral vectors
compared with the control vector.
Due to miR-125a’s reported involvement in CNS development
[26,27], along with a reported dysregulation in the CSF of
Alzheimer’s disease [28], we investigated whether a given target of
miR-125a would be affected by its overexpression. We found miR-
125a to be upregulated in HIV and HIV/MDD, and 15/20 of its
dysregulated target genes at the mRNA level to be upregulated
(Figure 4). We tested whether protein levels of one of its targets,
IFITM3, whose mRNA was also upregulated, would be affected
by overexpression in primary neuronal cultures. We found that
IFITM3 protein decreased in response to miR125a overexpression
at 3-5 days of post-miR125a induction, Figure 6a. We have
therefore provided in vitro evidence that miR-125a can alter
protein levels of IFITM3 in primary human neuronal cultures.
We also sought to verify whether overexpression of miR-22
would affect protein levels of the predicted target sTNFR1A
(soluble tumor necrosis factor receptor 1A). We chose to analyze
sTNFR-1A because it is an important mediator of TNF signaling
in the brain, it is suspected to play a role in a number of
neurodegenerative diseases [29] and is implicated in inflammatory
processes [30]. In our analysis, miR-22 showed significant target
bias, meaning that a disproportionate number of its targets were
dysregulated, including sTNFR-1A. Our in vitro study demon-
strated that overexpressing miR-22 caused reduction in sTNFR-
1A protein levels in the supernatant of primary human neurons.
Discussion
Limitations
Our study utilized a small sample size for a global gene-
expression study, increasing probability for false-positives. For that
reason, in our approach to the Target Bias Analysis, we analyzed
for and presented thresholds for significantly dysregulated genes
from a p,0.05 to also analyze for p,0.001, (Figure 3). Though we
attempted to use patient samples from matching decades of life,
given the resources available, we erred to minimize parameters
that would lead to degradation of RNA such as post-mortem
interval and brain pH. We chose a broad age-range in the control
group to account for a younger average-age in the HIV/MDD
group compared to the HIV-negative group (this is reflective of the
available tissue at our resource). Our control group age range was
24–50, our HIV was 45–56, and our HIV/MDD was 34–43; we
cannot rule out that our observations may be due to age group
differences.
Methodology and Platform
The miRNA array platform utilized in these experiments differs
significantly from hybridization gene microarrays with respect to
the chemical and physical dynamics. MiRNAs are highly
conserved and cluster into families that are evolutionarily related
and share sequence similarity. Further, by their nature of being
relatively short strands, and in cells, they hybridize to many
transcripts, increasing the potential for non-specific signals in a
hybridization-based platform, such as microarray, is high. The
PCR-based array employed here used a stem-looped multiplexed
primer set for cDNA synthesis and begins from the 59 end of the
small RNA, which are unique to the mature miRNA. This feature
precludes cDNA synthesis of other RNAs (even within the same
family), mRNA or otherwise, that exist with sequence similarity.
Our analysis was therefore specific for determining expression of
mature miRNA sequences present in the tissue, which we believe
to be functionally active.
Snapshot of Two Levels of Molecular Function in Vivo
As outlined in the model in Figure 1a, it is thought that perfect
sequence homology leads to degradation of the target mRNA,
while imperfect sequence homology results in interruption of
translation [8]. Tsang, Zhu, and Oudenaarden [31] outlined two
types of miRNA circuits, as shown in Figure 7. Type I circuits:
miRNAs and their corresponding targets are regulated together,
implying short-term modulation of protein translation and a
regulation of homeostasis of gene function. Type II circuits: where
miRNA circuits are inversely-regulated to corresponding targets;
which we hypothesize would be circuits involved in long-term
cellular phenotype, cell-lineage, or cell-differentiation functions.
The majority of dysregulated genes in our dataset were
dysregulated in the same direction as their target miRNA,
implying more Type I regulatory circuits in the adult brain tissue.
More Type II circuits have been characterized than Type I
circuits, as they are more readily identified and experimentally
verified, Figure 7 [31]. We posit that these circuits are involved in
tissue specificity and maintenance of cell identity, and would be
regulated together with transcription factors. Type I circuits, in
which the miRNA and its target are regulated together would
allow for modulation of protein translation, maintenance of
cellular homeostasis, or modulation of changes in local protein
concentrations. For the purposes of neuronal functions in the
Table 2. Characteristics of Cases in Affymetrix Microarray
Study.
Group Study ID Pathology MDD HIVE Age PMI Sex
HIV CC103 Min. Non-
Diganostic
abnormalities
None No 54 12 M
HIV CC141 Bacterial
leptomeningitis
None No 56 12 M
HIV CC147 Normal None No 50 15 M
HIV CA146 Normal None None 47 12 M
HIV/MDD CA110 Encephalitis 6 Mo Yes 43 12 M
HIV/MDD CA143 Normal 12 Mo No 38 7 M
HIV/MDD CC207 Normal 12 Mo No 56 12 M
HIV/MDD CA236 Encephalitis 6 Mo Yes 34 4 M
Abbreviations: MDD—Major depressive disorder, 6 Mo–within six months,
12 Mo–within 12 months, PMI–post-mortem interval to autopsy, HIVE –
neuropathologically confirmed HIV-encephalitis.
doi:10.1371/journal.pone.0010337.t002
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process for which miRNAs may play a crucial role [32]. Our
observations here indicate evidence for many Type I circuits in the
brain. This would provide a role for miRNAs regulating gene
functions at the level of protein translation. This is a possible
confounder when analyzing microarray data. Also, a protein may
be translated or activated without any apparent change in gene
transcript levels; and miRNAs are one of many mechanisms by
which this could occur. Further, others have recently verified
significant bias toward miRNA-mRNA-targets pairs being posi-
tively correlated using a empirical Bayes approach in Alzheimer’s
disease brain [33]. Together, this supports a hypothesis for Type I
circuitry involvement in homeostasis maintenance and Type II
circuitry involvement in tissue growth and differentiation.
MiRNAs may represent a common mechanism of cellular
dysfunction leading to diverse neurobehavioral deficits. One
miRNA, miR219, was shown to modulate NMDA-receptor-
mediated neurobehavioral dysfunction and is implicated in the
symptology of schizophrenia [34]. We found this miRNA to be
upregulated in HIV/MDD, Figure 1b. A miRNA profile of
Alzheimer’s Disease patients showed significant overlap with our
findings; 11/19 miRNAs found to be dysregulated in the FC in
AD [28] were dysregulated in our study in the same direction,
including miR125a, miR132, which have CNS developmental
roles [14], and were highly significant in our target bias analysis
(Figure 3).
The expression values from all miRNA targets are listed in
Table S2. Recently, the gene pathway database and networking
engine, Ingenuity Pathway Analysis [35], has added miRNAs to its
repertoire. With the goal of identifying pertinent biochemical
pathways, cell functions, or physiologic parameters, we analyzed
these miRNAs which served as significant circuits in our target
bias analysis; choosing those miRNAs which showed significant
target bias, described above.
Figure 3. Target Bias analysis of a subset of miRNAs from frontal cortex in HIV and HIV/MDD conditions. MiRNAs dysregulated at least
twofold in HIV or HIV/MDD are analyzed. Four windows of analysis are depicted: mRNAs dysregulated in HIV or HIV/MDD at p,0.05, p,0.01,
p,0.005, and p,0.001. For each window, a list of dysregulated mRNAs is generated (n) from the Affymetrix U133 Plus 2.0 array (containing probes
for N unique genes) which calculated relative quantification (RQ) of gene expression in Condition vs Control, data shown in Table S2. For each miRNA,
a list of all targets present on the array is generated (m); from that list of targets, the number k targets are found to be significantly dysregulated
within each of the four windows. Using cumulative hypergeometric distribution from SPSS software [41], we calculated the probability that k targets
would be dysregulated from a list of size n genes, given that there are m targets on the gene array of the population N genes. (Using the function:
P=1-cdst.hypergeo(k,n,N,m) in SPSS). The color scale depicts the probability for target bias for each of 97 miRNAs and corresponding windows, with
dark blue to white indicating 0.0,P,0.5. The miRNAs were sorted by their target biases using Hierarchical Clustering algorithm of Genepattern
software. The gene expression in HIV/MDD of genes which are targets of miRNAs that show significant target bias is illustrated in Figure 4.
doi:10.1371/journal.pone.0010337.g003
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Until now, our analysis centered on miRNAs as circuits in gene
regulatory networks, but genes themselves may have target sites for
multiplemiRNAs.InTableS2,somegenesappearmultipletimesas
targets of different miRNAs. Shalgi et al [24] identified genes as
‘‘hubs’’ of miRNA regulation that were under the post-transcrip-
tional regulation of dozens of miRNAs. In plotting the distribution
of the number of dysregulated miRNA sites in the dysregulated
genes (Figure 8), we found the majority of our dysregulated genes
had 39UTR target sequences for few miRNAs (median of 4, and
interquartile range 2–7), but a minority were determined to be
extreme values in the distribution plot of Figure 8 with 16–18
miRNA target sites of dysregulated miRNAs. These genes are:
cullin 4B (CUL4B, 8450), forkhead box P2 (FOXP2, 114142)
regulator of g-protein signaling 10 (RGS10, 54290), chloride
intracellular channel 1 (CLIC1, 1192), endosulfine a (ENSA,
2029), and colony stimulating factor receptor 2a (CSF2RA, 1438).
Pathway analysis of this small list of genes using Ingenuity
Systems’ software revealed interesting functions in support of the
hypothesis that they would be ‘‘hubs’’ of cellular or physiologic
function and is illustrated in Figure 9 [35]. FOXP2 is a
transcription factor important for some neuronal functions
including reflex, development of cerebellum, developmental
disorders, and is implicated in schizophrenia. RGS10 was
upregulated and is functionally relevant to microglia quantity
and cell death of neuronal hybrid cells. CUL4B was upregulated in
MDD and forms a complex that functions as an E3 ubiquitin
ligase that catalyzes polyubiquitination of specific protein sub-
strates. CUL4B is required for proteolysis of regulators of DNA
replication, and is thereby involved in cell cycle or DNA repair.
CLIC1 is a nuclear chloride ion channel and regulates
fundamental cellular processes including stabilization of mem-
brane voltage potential, transepithelial transport, maintenance of
intracellular pH, and is increased in our findings in FC of HIV
patients with MDD compared to those without. Interestingly,
others showed an increase after exposure to dexamethasone, an
activator of glucocorticoid receptor [36]. ENSA was downregu-
lated in MDD, and encodes the regulatory subunit of an ATP-
Figure 4. Targets of dysregulated miRNAs in MDD patients (mRNA relative quantification values). The gene expression values were
determined using Affymetrix U133 Plus 2.0 array and compared HIV/MDD vs HIV alone from frontal cortex tissue from 6 patients in each group; one-
way ANCOVA compared the two groups and were different at p,0.05 significance are listed in Table S1. The gene expression is plotted for those with
39UTR seed sequences for miRNAs that showed highly significant target bias. The direction of the dysregulation of the miRNA is indication by the
arrow; for miR-367, miR-136, and miR-125a, the majority of targets are dysregulated in accordance with the miRNAs; while for miR-502, the majority of
targets are anticorrelated. q or Q indicate the miRNA was upregulated or downregulated, respectively, in the array.
doi:10.1371/journal.pone.0010337.g004
Figure 5. Lentiviral overexpression of (A) miR-22 and (B) miR-125a in primary neuronal cultures.
doi:10.1371/journal.pone.0010337.g005
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channel activity. CSF2RA, upregulated in MDD, is a transmem-
brane receptor, a member of the cytokine receptor family, and its
signaling controls the production and differentiation of macro-
phages. According to Ingenuity, it is implicated in many diseases
including schizophrenia and HIV infection [35].
In vitro, we verified an effect of two miRNAs on two targets.
Both miR-125a and miR-22 were found to be upregulated in our
analysis of HIV-infected individuals. The target genes of these
miRNAs were also upregulated, indicating Type-I circuitry. We
provide evidence that the induction of these dysregulated miRNAs
impact the protein translation of predicted mRNA targets.
Specifically, we chose an intracellular membrane protein, IFITM3
and a secreted protein involved in neuroinflammation, sTNFR1A.
Like other studies, the miRNA-mRNA target pairs here were
positively correlated, and we showed in vitro, a decrease in protein
content. These results support a functional outcome of positively
correlated miRNA-target transcription to be potentially allowing
for a buffer-effect of protein translation for homeostatic mainte-
nance. A logical extension to these experiments is to test in a high-
throughput manner, the protein content of these targets under the
different developmental and disease-states and to determine which
upstream factors first postulated by Tsang [31] differentially
regulate miRNA-target transcription.
Clinical Relevance
Major depressive disorder (MDD) is a clinically defined entity
with little understanding as to the underlying pathological
substrate. Biologically, MDD is characterized by disruption of
neurotransmitters, especially serotonin and noradrenaline, which
Figure 6. (A) Decreased protein production of IFITM3 in miR-125a overexpressing neuronal cells and (B) decreased secretion of sTNFR-1A in miR-22
overexpressing neuronal cultures.
doi:10.1371/journal.pone.0010337.g006
Figure 7. Two types of miRNA circuits in gene regulatory
networks. In Type I, targets (T) are regulated together with the miRNA;
or changes in expression would be correlated. In Type II, the upstream
factor regulates the target and the miRNA contrarily, changes in
expression would be anticorrelated. Reprinted from Molecular Cell, 26:5,
Tsang, Zhu, and van Oudenaarden, ‘‘MicroRNA-Mediated Feedback and
Feedforward Loops are Recurrent Network Motifs in Mammals,’’
Copyright (2007), with permission from Elsevier.
doi:10.1371/journal.pone.0010337.g007
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strated significant reduction of glial cell number in the cingulate
and dorsolateral prefrontal cortical regions [37,38], while Evans et
al., [39] reported dysregulation of the trophic factors fibroblast
growth factor (FGF) 2 and 9 in the brains of individuals with
MDD. We recapitulated the alteration in FGF2 and FGF9 in
human brain aggregates exposed to cortisol [40]. There appears to
be a disturbance of trophic factors and glial cell function in
addition to neurotransmitter abnormalities contributing to MDD.
Unfortunately, the prevalence of MDD in the HIV population
is still very high, despite a sharp fall in mortality rates due to
effective antiretroviral treatment. It is possible that in this
treatment era, living with chronic HIV infection may result in
long-term neuropathological changes that predispose to MDD.
For example, it is known that HIV is associated with a range of
inflammatory pathologies, neuronal loss and dendrite-synaptic
damage [41]. These neurodegenerative changes have been linked
to neurocognitive impairment [42,43,44]; however, it is also
possible that these changes potentiate MDD [38].
Large-scale gene expression analysis is daunting and the
biological significance of the findings is difficult to ascertain. In a
microarray analysis comparing gene expression in the CNS of
HIV-infected individuals with neuropathologically confirmed
HIV-encephalitis, our group reported changes in transcription of
genes involved in signaling and the cytoskeleton (Accession
Number GDS1726) [45]. Changes in the amount of a particular
mRNA might not necessarily correlate to changes in function of
protein for which it codes. Additionally, the function of a gene (i.e.,
protein translation) could be altered without concordant changes
in transcript abundance. One mechanism by which these apparent
digressions occur is through alteration of the miRNA repertoire in
the tissue.
Currently, many gene-expression studies use microarray
technology, the basis for which is RNA transcript hybridizing to
immobilized probes which correspond to tens of thousands of
defined sequences. The platform is analyzed by comparing the
signal, through an enzymatic or fluorescence reaction, of a test-
sample (ie: Disease patient) compared to some reference sample
(ie: Control or healthy subject). In the current study, we augment
information from microarray gene expression with analysis of
miRNA profiling through a PCR-based array. Since the gene
expression and miRNA expression analyses were performed from
the same brain region, FC, on the same panel of patients, we are
able to consider two levels of biology and identify MiRNAs as
circuits in gene regulatory networks pertinent to molecular
homeostasis in adult human FC. Future studies may seek to
analyze other brain regions systemically using a similar method-
ology. We chose to begin with frontal cortex matter because it is
the site of greatest damage in cortex by HIV and our group
previously showed changes in the FC in MDD [38].
While the results we present are correlative in nature, and
provide only a snapshot, it is quite telling that a viral infection;
absent from other confounding factors such as drug dependence or
neurocognitive impairment, impacts the miRNA repertoire of the
FC. We also found that a subset of miRNAs were dysregulated,
generally downregulated, in the FC of patients grouped by
psychiatric diagnosis, (HIV/MDD compared to HIV alone).
Cotter et al showed decreased synaptic and dendritic density in
CNS of MDD patients [38]. Ashraf and Kunes hypothesized that
miRNAs might serve as the molecular etiology for memory and
Figure 8. Number of dysregulated miRNA 39UTR sites in dysregulated mRNAs. The number of miRNA targets sites for each dysregulated
gene is counted and distribution shown (bottom) with outlier plot (top), six genes were outliers with 16–18 targets sites while the median was four
target sites for each mRNA.
doi:10.1371/journal.pone.0010337.g008
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underlying protein synaptic protein synthesis associated with
memory [32,46]. While it is accepted that neurons are not infected
by the human immunodeficiency virus, we hypothesize that low-
grade, chronic neuroinflammation, or neurovascular alterations
owing to activated microglia or infiltrating monocytes would cause
paracrine signaling to neurons leading to activation or suppression
of RNA transcription, which would be consistent with our
observation of miRNA-dysregulation being chromosomally clus-
tered around certain regions of the genome. Interestingly,
Manakov and others showed that miRNAs clustered on
Chromosomes 14 and X were downregulated during neuronal
development and synapse formation, concurring with our study in
HIV and MDD [26].
Conclusion
While other studies that integrated both miRNA and mRNA
quantification focused on developmental and cellular biology, our
study focused on a single time point in adult human brain tissue.
For comparison, we compared healthy with infection and infection
with a psychiatric disorder. MDD and other psychiatric disorders
are characterized physiologically by pertubations in neuroendo-
crine system, the putative substrate that acts on the brain to give
the psychiatric effect. We found a repertoire of miRNAs
downregulated in MDD along with related gene-targets and gene
‘‘hubs’’ of miRNA activity. This may potentially serve as the
molecular link between the neuroendocrine pertubations and the
subtle pathologic changes that occur in MDD outlined above. The
methodological platform for quantitation of miRNAs measured
amplification of PCR reaction in solution rather than hybridiza-
tion to immobilized complementary strands, it is highly sensitive
and reproducible; and may even be more cost-effective than the
traditional array platforms. Finally, our target bias analysis, which
analyzed the results of a gene array yielding a host of dysregulated
transcripts from the perspective of dysregulated MiRNAs–a
potentially powerful analytic tool applicable to many tissues,
diseases, developmental conditions, and species that will help
elucidate the regulatory role of miRNAs in complex molecular
networks.
Materials and Methods
Subject Acquisition
Ethical Statement. The University of California San Diego
Institutional Review Board approved the work included in this
project for continuing use of anonymous pathological specimens
and clinical data. Written informed consent was obtained from all
subjects included in the study.
Microarray. For the microarray study, we included eight
HIV+ cases from the HIV Neurobehavioral Research Center at
the University of California San Diego. Cases had neuromedical
and neuropsychological examinations within a median of 6
months before death. Most cases died as a result of acute
bronchopneumonia or septicemia, and autopsy was performed
Figure 9. Pathway analysis of mRNAs and miRNAs. MiRNAs were chosen on the basis of their highly significant target bias, and mRNAs chosen
that had a high number target sequence sites in 39UTRs. Ingenuity Pathway Analysis algorithm, database, and software was used to illustrate the
interrelationships and functional relationships.
doi:10.1371/journal.pone.0010337.g009
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diagnosis of MDD, two of whom also had HIV encephalitis.
Table 2 summarizes the cases. At time of autopsy, tissue from the
frontal lobe was flash frozen and stored indefinitely at 280uC.
MicroRNA Array. From the patient-pool, three MDD and
non-MDD cases were chosen on the basis of closely matching age,
PMI, and excluding a history of substance dependence or abuse,
and having a major depressive episode within six months, as
determined by meeting DSM-IV criteria by a trained psychiatrist.
Because of limited resources and requirement to closely match
cases, all cases were male. Matched control cases were HIV-, had
no history of psychiatric disorder and causes of death were
unrelated to brain injury.
Microarray
To determine the differentially expressed genes between
patients with HIV and HIV+MDD, patient cDNA was hybridized
to the Affymetrix U133+2 chip (Affymetrix, USA), using standard
methods suggested by the manufacturer. All data are MIAME
compliant and the raw data were deposited in the Gene
Expression Omnibus (GEO) Accession Number GSE17440. The
resulting *.cel files were imported into the Partek Genomics Suite
software (Partek Inc, St. Louis, MO, USA) [47] to analyze probe
intensity and to determine the differential gene expression between
the groups.
MicroRNA Array
Ten mg tissue from cortical grey matter of FC was dissected and
RNA was isolated following instructions of MirVana RNA
isolation kit (Applied Biosystems). 900 ng RNA from each subject
was pooled into their respective groups (for a total of 2700 ng
RNA). The RNA was reverse-transcribed using a MicroRNA
Multiplex Primer set and MicroRNA Reverse Transcription kit
(Applied Biosystems), cDNA was stored at 220uC. Equivalent to
800 ng of the cDNA product was applied to TaqMan MicroRNA
Array v2 and reactions monitored and analyzed according to
manufacturer’s protocols in an Applied Biosystems 7900HT Fast
Real-Time PCR System, applying the low density array settings
and results interpreted in Applied Biosystems’s RQ Manager
software [48]. For relative quantification (RQ), the hhCT method
was used. The array supplied quadruplicate wells for mammalian
U6 RNA as an endogenous control, along with RNU44 and
RNU42; we determined RNU44 was the optimal endogenous
control in our samples, and the RQ was calculated using the
Control group as the calibrator. The arrays were performed in
technical triplicates. These array data were deposited to the GEO
database under the Accession Number GSE17440.
Quantitative PCR of miRNA
Non-pooled and pooled RNA isolated above along with a
second round of RNA isolation was reverse-transcribed and
analyzed separately with TaqMan RT-PCR microRNA assays
(Applied Biosystems). The reverse transcription is carried out with
a specific stem-looped primer step for each individual miRNA
followed by qPCR using FAM-labeled probes in 384-well optical
plate in Applied Biosystems 7900HT Fast Real-Time PCR
System. The following RNAs (Applied Biosystems product ID#s)
were analyzed: MammU6 (#4395470), RNU44 (#4373384),
miR-122 (#4395356), miR-29a (#4395223), miR-367
(#4373034), miR-142-5p (#4395359), miR-154 (#4373270),
miR-214 (#4395417), miR-193a-3p (#4395361), miR-495
(#4381078), miR-125a-3p (#4395310), miR-134 (4373143). The
assays were performed in technical triplicate and biological
duplicate.
In vitro Lentiviral Expression of miRNAs
Primary human neuronal cultures were maintained according
to our past procedures [49]. Lentiviral vectors were obtained from
Origene (Rockville, MD) which contained human miR-125a
(#SC400749) and human miR-22 (#SC400286) mature sequenc-
es on a pCMV-MIR backbone. Neuronal cultures were exposed to
10 multiples of infection (MOI) 0, 1, 3, 5 days, RNA isolated and
miRNA quantified by qPCR.
Western Blotting and ELISA
Total protein cell lysates from cells treated exposed to miR-125a
were obtained by incubation with a lysis buffer containing 0.15 M
NaCl, 5 mM EDTA, 1% Triton X-100, 10 mM Tris-HCl, and
1% SDS with Complete Proteases Inhibitor Cocktail (Roche, Palo
Alto, CA). Ten mg protein was loaded into 4-10% gradient
polyacrylamide gel, separated by electrophoresis, and transferred
to PVDF membrane. After blocking with 10% non-fat milk in
PBS-0.3%Tween-20, membrane was probed overnight with rabbit
anti IFITM3 (#10410, Abnova, Taipei, Taiwan) overnight at 4uC.
Blots were visualized after incubating with secondary, peroxidase-
conjugated anti-rabbit antibody (#PI-1000, Vector, Burlingame,
CA) and incubated with chemiluminescence reagent (Pierce,
Rockford, IL).
Two-hundred mL supernatant was removed at 1, 3, 5 days, and
immediately following exposure to 10 MOI of miR-22 lentiviral
vector. Media were replaced with neurobasal growth media
following aliquot removal. In order to alleviate effect of differential
evaporation, volume in each well was adjusted to 500 mL
immediately prior to supernatant sample collection. Supernatant
was stored in 10% bovine albumin-blocking solution to prevent
analyte loss to labware. Samples were diluted 1:2 and sTNFR1A
was quantified using ELISA following manufacturer’s protocols
(kit DRT100, Quantikine, Minneapolis, MN).
Data Analysis
The Taqman MicroRNA Array v 2 (Applied Biosystems) was
performed in triplicate and yielded qPCR data analyzed in
Applied Biosystems RQ Manager Software. Relative Quantifica-
tion (RQ) was determined by the hhCT method using RNU44 as
an endogenous control transcript and the Control group signal as
the calibrator. For illustration, we reported the Log2(RQ). Briefly:
hCTSample=CT RNU442CTmiRNA; hhCTHIV=hCTControl2hCTHIV;
and RQHIV=2
2hhCTHIV [50].
Since the samples for the microarray were not pooled, we could
perform one-way analysis of covariance (ANCOVA) for covari-
ates, age, PMI, MDD status, viral load, were inputted into the
model. Robust Multichip Analysis (RMA) in Partek gene
expression software was used to perform the ANCOVA to
determine ratio by MDD-positive vs MDD negative and calculate
p-values for each probe.
To determine the chromosomal locations of the miRNAs, the
data (Chromosome number and basebair location) were extracted
from Mirbase database, and the locations of the miRNAs which
were dysregulated at least twofold in either direction was listed and
mapped. The nearest neighbor of a dysregulated miRNA was
calculated (only for neighbors on the same chromosome) to
determine nearest neighbor distance for each dysregulated miRNA.
Using JMP statistical software, a distribution plot was generated
showing the distribution of the miRNA-nearest-neighbor distances
for the dysregulated miRNAs to plot median and interquartile
ranges. For comparison, a bootstrap randomization method was
used. We randomly choose from a list of all miRNAs and calculated
the nearest-neighbor distance if randomly chosen, this was
performed 999 times and the distribution is shown.
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miRNA as in Tsang et al [22]. A list of targets of miRNAs for each
dysregulated miRNA was generated from data extraction from
Mirbase databse. Each miRNA had number, m, of unique genes
that were both possible targets of a particular miRNA and present
on the Affymetrix gene chip. The number, N, of genes expressed
on the Affymetrix chip was determined. For a particular
significance window (i.e.: p,0.05, p,0.01, p,0.005), a number,
n, genes were dysregulated in the microarray. Each dysregulated
miRNA also had a number, k, of possible targets that were also
dysregulated at given signficance cutoff. The cumulative hyper-
geometric probability distribution (sampling without replacement)
was used to calculate the probability that at least k targets of a
particular miRNA would be on a list of size n dysregulated genes,
given that m possible targets are on a chip of probeset size N. This
probability was determined in SPSS [51] using the function: P=1-
cdst.hypergeo(k,n,N,m) and illustrated in color code.
In orderto determinewhether some genes that weredysregulated
had a disproportionate amount of miRNA 39UTR target sites
which were also, dysregulated, we counted the number of 39UTR
sites in each and plotted the distribution using JMP software. There
wasamedianof4sitesfordysregulatedmiRNAsinthedysregulated
genes, with four genes having up to 16–18 target sites being outliers
as determined by JMP statistical software.
Supporting Information
Figure S1 (A) XenoRNA assay. (B) Polyacrylamide electropho-
resis and SybrGold staining of total RNA. Pooled RNA samples run
on the array-cards were serial tenfold diluted and known quantity of
xeno-added, ACTB and Xeno-RNA were measured by TaqMan
reverse-transcription-PCR. Plotted are CT versus mass RNA,
ACTB CT values increased proportionately with decreasing RNA
and Xeno-RNA remained unchanged across dilutions; indicating
no RNAses and consistent reverse transcription efficiency.
Found at: doi:10.1371/journal.pone.0010337.s001 (2.12 MB
PDF)
Figure S2 Amplification plots for MammU6 and RNU44 from
(A) the miRNA Array 2.0 and (B) individual qPCR reactions of
subjects. (A) From the array, it was apparent that in HIV/MDD,
MammU6 was differentially expressed compared to the other
groups, which is confirmed (B) in individual, non-pooled, samples
performed in biological duplicate.
Found at: doi:10.1371/journal.pone.0010337.s002 (12.51 MB
PDF)
Figure S3 Pooled and Non-pooled Expression by Group of
SelectedmiRNA’s Using qPCR.The pooled RNAsamplesthat had
been included in the Taqman miRNA Array v2.0 was subjected to
reverse-transcriptase real-time PCR for primers/probes for miR134
(Accession Number 406924), miR154 (Accession Number 406946),
miR132 (Accession Number 406921), miR122, miR214 (Accession
Number 406996), miR29a (Accession Number 407021), miR495
(Accession Number 574453), miR193a (Accession Number
406968), miR125a, and miR367. The RNA from individual
subjects that comprised the pooled samples were also subjected to
RT-PCR and plotted together with the pooled sample. (ClosedBox)
Pooled Control, (Open Box) Control subjects, (Closed Triangle)
Pooled HIV, (Open Triangle) HIV subjects, (Closed Circle) Pooled
HIV/MDD, (Open Circle) HIV/MDD subjects. Q indicates no
amplification for a subject.
Found at: doi:10.1371/journal.pone.0010337.s003 (1.05 MB TIF)
Figure S4 Reproducibility - Effect of Tissue Dissection. RNA
was isolated on two separate occasions following the miRVana
protocol from the frontal cortex tissue and subjected to RT-PCR
for miR122 (diamond), miR125a-3p (square), miR132 (triangle),
and miR134 (X), and miR495 (asterisk). RNU44 was used as an
endogenous control, and the Log2(RQ) is plotted (median and
range of technical triplicate measurements); for calibrator, the
median control subject was used. The signal from the RNA
Extraction A vs RNA Extraction B is plotted; perfect reproduc-
ibility would be along the x=y line.
Found at: doi:10.1371/journal.pone.0010337.s004 (0.51 MB
PDF)
File S1 For analysis and visualization of heatmap with
Genepattern software, used with File S2.
Found at: doi:10.1371/journal.pone.0010337.s005 (0.02 MB
TXT)
File S2 For analysis and visualization of heatmap with
Genepattern software, used with File S1.
Found at: doi:10.1371/journal.pone.0010337.s006 (0.01 MB
TXT)
File S3 For analysis and visualization of chromosomal locations
of miRs’ genomic locations, for use with the UCSC Genome
Browser, used with Files S4 and S5.
Found at: doi:10.1371/journal.pone.0010337.s007 (0.01 MB
TXT)
File S4 For analysis and visualization of chromosomal locations
of miRs’ genomic locations, for use with the UCSC Genome
Browser, used with Files S3 and S5.
Found at: doi:10.1371/journal.pone.0010337.s008 (0.00 MB
TXT)
File S5 For analysis and visualization of chromosomal locations
of miRs’ genomic locations, for use with the UCSC Genome
Browser, used with Files S3 and S4.
Found at: doi:10.1371/journal.pone.0010337.s009 (0.00 MB
TXT)
Table S1 One-Way ANCOVA - Affymetrix Array of Genes
HIV vs HIV/MDD.
Found at: doi:10.1371/journal.pone.0010337.s010 (0.05 MB
TXT)
Table S2 MiRNA’s which are twofold dysregulated and their
dysregulated target-genes, sorted by significance.
Found at: doi:10.1371/journal.pone.0010337.s011 (0.04 MB
TXT)
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